Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial

Azacitidine (Aza) combined with donor lymphocyte infusions (DLI) is an established treatment for relapse of myeloid malignancies after allogeneic transplantation. Based on its immunomodulatory and anti-leukemic properties we considered Lenalidomide (Lena) to act synergistically with Aza/DLI to impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Schroeder, Thomas, Stelljes, Matthias, Christopeit, Maximilian, Esseling, Eva, Scheid, Christoph, Mikesch, Jan-Henrik, Rautenberg, Christina, Jäger, Paul, Cadeddu, Ron-Patrick, Drusenheimer, Nadja, Holtick, Udo, Klein, Stefan, Trenschel, Rudolf, Haas, Rainer, Germing, Ulrich, Kröger, Nicolaus, Kobbe, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620594/
https://www.ncbi.nlm.nih.gov/pubmed/37259567
http://dx.doi.org/10.3324/haematol.2022.282570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620594/
https://www.ncbi.nlm.nih.gov/pubmed/37259567
http://dx.doi.org/10.3324/haematol.2022.282570

Ejemplares similares